EXHIBIT 10.30


 


First Amendment to
Licensing Agreement


 


This
First Amendment to Licensing Agreement
("First Amendment")
is to memorialize the agreement between
PharmaCyte Biotech, Inc.,
formerly Nuvilex, Inc.
("Licensee")
and Austrianova Singapore Pte Ltd ("Licensor")
to amend, effective as
of June 30, 2015, the Licensing
Agreement between the parties dated
as of 1 December 2014 ("Licensing
Agreement") as follows.
The defined terms in the Licensing Agreement
have the same meaning
as the terms in this
First Amendment.


 


		A.	The Parties entered into
the Licensing Agreement to,
among other things provide
Licensee with an exclusive worldwide license
to use the Cell-in-a-Box® Trademark and
its Associated Technology with
genetically modified non-stem cell
lines specifically
designed to activate
members of the Cannabinoid
family of molecules
to: (i) conduct research; (ii) have
made by Licensor; (iii)
use in preclinical studies and clinical trials;
(iv) obtain marketing approval;
(v) and market and
sell products and treatments
utilizing the Cell-in-a-Box®
Trademark and its Associated
Technology world-wide;



 


		B.	The Licensing Agreement provides
Licensee shall pay
Licensor an initial payment
("Upfront Payment") of
Two Million Dollars US (USD $2,000,000 .00.
It further provides
that Licensee shall make periodic
monthly partial payments of the
Upfront Payment in amounts to be
agreed upon between the Parties prior to each such payment
being made; provided, however the Upfront Payment shall
be paid in full by
no later than June 30,
2015.; and



 


		C.	The Parties desire to extend
the date by which
the Upfront Payment
must be made by Licensee.



 


NOW,
THEREFORE, for good and valuable consideration, the receipt
and sufficiency of which are hereby
acknowledged by the Parties,
the Research Agreement is hereby
amended as follows:


 


1.  
Section 2.2 of
the Licensing Agreement shall be
deleted and the following inserted in its place:
"Subject to the
terms of this Agreement ,
Licensee shall pay Licensor
an initial payment ("Upfront
Payment") of Two
Million Dollars US (USD
$2,000,000.00).
Licensee shall make periodic monthly
partial payments of the Upfront Payment in amounts
to be agreed upon between
the Parties prior to each
such payment being made: provided,
however, the Upfront
Payment shall be paid in full by
no later than December
31, 2015."


 


2.  
Section 8.1.2.
of the Licensing Agreement
shall be deleted and the following inserted in its
place: "Similarly,
the License may be
terminated and all rights
shall revert to Licensor if any
of the following events do not occur within the
timeframe set forth in
this Agreement provided that
Licensor gives Licensee thirty (30)
days' notice prior
to the effective date of termination and Licensee
fails to cure the following events
during the thirty (30)
day period: (i)
if Licensee fails to
pay in full the Upfront
Payment by December 31,
2015; (ii) if Licensee does not enter
into a research program
involving the Scope
of the Agreement within three (3) years of the Effective
Date; or (iii) if
Licensee does not enter
clinical trials or their equivalent for a Product within seven
(7) years from the Effective Date."


 


3.   
Except as provided
in this First Amendment , all
of the other provisions of the
Licensing Agreement shall remain in full force and
effect.


 


IN
WITNESS WHEREOF , each Party
has executed this First
Amendment by its duly authorized representative
as of the date first
written above.


 


 





	PharmaCyte Biotech, Inc.	Austrianova
Singapore Pte Ltd
	 	 
	/s/ Kenneth L. Waggoner               	/s/ Brian Salmons              
	By: Dr. Kenneth L. Waggoner

                                    Title:
Chief Executive Officer

                                    
	By:

        Title:
	Dr. Brian Salmons
 Chief
Executive Officer